Dare Bioscience, Inc. · NASDAQ:DARE
Dare Bioscience — Investor Presentation (June 2026)
38 slides from Dare Bioscience's investor presentation, Jun 22, 2026
Slide 1: Dare Bioscience Corporate Deck
CORPORATE DECK Wy) DARE BIOSCIENCE DAREBIOSCIENCE.COM | NASDAG: DARE DARE BIOSCIENCE, ALL RIGHTS RESERVED
Slide 2: Forward-Looking Statements & Disclaimers
AREBIOSCIENCE rv Ny Forward-Looking Statements & Disclaimers This presentation is for informational purposes only and is not an offerto sell or a solicitation of an offer to buy any securities of Daré Bioscience, Inc. ("Daré" or the “Company’). This presentation discusses potential future drug and m
Slide 3: Dare to Push Women's Health Forward
AREBIOSCIENCE DARE TO PUSH WOMEN'S HEALTH FORWARD Bioscience that’s 100% for her. A " a ~S ae Se
Slide 4: Investment Highlights
DAREBIOSCIENCE Investment Highlights rr Exclusive Focus on Women's Health Purpose-built portfolio addressing large, underserved markets across women’s health. Commercial Launch Revenue expected from product sales in 2026 with the goal of becoming profitable as product sales scale B\ Clinical and Evi
Slide 5: Dare for Her at Every Stage of Life
AREBIOSCIENCE Dare for Her at Every Stage of Life PLAY PLAN SUPPORT RECLAIM FIGHT Confidence and freedom to live life Empowering your choices for today Care that supports you and the life Solutions to help you feel like Innovations to help you thrive and your way. and tomorrow. you're building. your
Slide 6: Pipeline Focused on Supporting Every Woman at Every Stage
AREBIOSCIENCE 0) Pipeline Focused on Supporting Every Woman at Every Stage Women's health is not a single condition. It is a lifelong healthcare journey affecting every woman, at every stage of life. >) Designed to maintain a Designed for her healthy vaginal microbiome sexual experience Commercial L
Slide 7: Why Women's Health, Why Now?
AREBIOSCIENCE Why Women's Health, Why Now? That is Not a Niche. That is a Significant Market Opportunity. 27% |80% of all blockbuster of all U.S. healthcare pharmaceutical products purchasing decisions are women's health drugs’ | are made by women? 1, 1QVIA Monthly Global MIDAS $ Const-Exchng (MNF)
Slide 8: Significant Non-Dilutive Funding From Leading Institutions
AREBIOSCIENCE Significant Non-Dilutive Funding From Leading Institutions Over $75 Million Awarded to Date Validates Approach and Need Gates Foundation Committed $2.5 billion through 2030 to advance women’s health research and innovation $60M+ AWARDED TO DARE “\) DARE ® NHC (contraception) // BIOSCIE
Slide 9: Data Driven Development. Not Just Another Online Compounder.
AREBIOSCIENCE Data Driven Development. Not Just Another Online Compounder. Built on Science, Clinical Evidence, FDA Development and Product Quality 01 02 03 Clinical Development Proprietary Products Commercial Platform Conducting clinical studies Novel formulations and * DARE Health Hub Generates pr
Slide 10: A Commercial Company with a Purpose-Built Women's Health Platform
AREBIOSCIENCE ACommercial Company with a Purpose-Built Women's Health @
Slide 11: Flora Syne LF5
DAREBIOSCIENCE DARE TO RESTORE™ Flora Syne LFS™ Non-hormonal probiotic vaginal capsule designed to restore microbiome balance and support lasting comfort eo Commercial Launch Targeted June 2026 @) Available without a prescription (41) Vaginal capsule formulated with Limosilactobacillus (all ay ferme
Slide 12: Sildenafil Cream
DAREBIOSCIENCE DARE TO PLAY™ Sildenafil Cream* Proprietary topical formulation of the active ingredient in an erectile dysfunction drug (Viagra®) + Prescriptions Dispensing Targeted Summer 2026 Prescribers Already Writing and Patients Engaging No FDA-approved treatments for female sexual arousal dis
Slide 13: Turning Clinical Relationships Into Commercial Momentum
Turning Clinical Relationships Into Commercial Momentum Years of product development have created trusted relationships with the providers most likely to adopt new women's health solutions 8 Clinical Relationships @-® Commercial Advantage Built Through Development & Long-standing engagement with OBG
Slide 14: Integrated Commercial Platform Designed for Scalable Growth
oantscscaic D Integrated Commercial Platform Designed for Scalable Growth Driving patient acquisition, engagement, and portfolio expansion through a unified women's health ecosystem OBGYN and women's health specialist engagement + Product recommendations and office-based awareness + Trusted clinical
Slide 15: DARE Health Hub: Direct-to-Patient Growth Engine
DAREBIOSCIENCE DARE Health Hub: Direct-to-Patient Growth Engine Central Commercial Platform DARE eae nue Welcome to the DARE Health Hub Products built by biotech, PLAY” designed for her. Product education ter or log in to manage prescriptions, update personal information, ‘and shop with confidence.
Slide 16: Development Pipeline
Development Pipeline Robust development strategy to continue to fuel commercial product portfolio
Slide 17: Ovaprene: Hormone-Free Monthly Intravaginal Contraceptive
DAREBIOSCIENCE DARE to PLAN™ Ovaprene: Investigational Hormone-Free Monthly Intravaginal Contraceptive Ongoing Phase 3 Study with Topline Data Expected 20271 Hormone-Free: Unique dual action MOA (spermiostatic & barrier), no hormonal safety concerns ( g | 86% - 91% expected typical use effectiveness
Slide 18: DARE-HPV
AREBIOSCIENCE DARE-HPV* Investigational Antiviral Vaginal Insert For Persistent High-Risk HPV Infection + Phase 2 Study Commenced May 20261 A proprietary fixed-dose formulation of lopinavir and ritonavir? in a soft gel vaginal insert (4 Majority of women achieved no dysplasia and anll undetectable H
Slide 19: DARE-HRT1
AREBIOSCIENCE DARE-HRT1 Monthly Hormone Therapy for Menopause Symptoms + Phase 3-Enabling Activities Underway A proprietary intravaginal ring designed to continuously deliver bio-identical estradiol and progesterone over 28 days Statistically significant improvements in hot flashes, night sweats, va
Slide 20: DARE-FRT1
AREBIOSCIENCE DARE-FRT1 Investigational Sustained-Release Progesterone Ring for Pregnancy Maintenance + Phase 1 Study Preparation Underway A proprietary intravaginal ring designed to deliver bio-identical progesterone as an alternative to daily injections or vaginal gel i Toa \ | Potential IND appli
Slide 21: Multiple Pipeline Expansion Opportunities from Earlier Stage Programs
AREBIOSCIENCE Multiple Pipeline Expansion Opportunities from Earlier Stage Programs” Australia R&D Cash Rebate Theramex National nsitutes ot Health Nationa Institutes of Health ‘Foundation grant up to ~849M" Program DARE-PDM1* Casea S* DARE 204/214" DARE- LARC1* DARE-RH1 DARE-PTB2 Vaginal diclofenac
Slide 22: Corporate Overview
Corporate Overview
Slide 23: Financial Snapshot
DAREBIOSCIENCE Nasdaq: DARE Financial Snapshot Expected to Start Generating Product Revenue with Commercial Launch of Flora Sync LF5 in June 2026 and Upcoming Launch of DARE to PLAY in Summer 2026 C8 <a all mR ~$18.5M + ~$29M * 622K + ~15M Cash’ Market Cap Trading Volume Shares As of March 31, 2026
Slide 24: Management Team
AREBIOSCIENCE Management Team 2 ah Sabrina Martucci Johnson David Friend, PhD MarDee Haring-Layton Jessica Hatheway Annie Thurman, MD, FACOG Mark Walters CEO & President Chief Scientific Officer Chief Accounting Officer VP, Clinical Operations Medical Director VP, Operations abeth Proos Robert Charb
Slide 25: Multiple Near-Term Catalysts with Potential for Meaningful Value Creation
DAREBIOSCIENCE Multiple Near-Term Catalysts with Potential for Meaningful Value Creation PRODUCT / PROGRAM GRANT-FUNDED U DARE to PLAY? i, (Sildenafil Cream) DARE to RESTORE (Flora Syne LF5™ Probiotic) Ovaprene® (Contraceptive) , _DARE-HPV 2 (HPV Therapy) DARE to RECLAIM (Menopause hormone therapy I
Slide 26: Why Daré, Why Now.
AREBIOSCIENCE Why Daré, Why Now. Transitioning to a Commercial-Stage Company with Two Revenue-Generating Products Launching and a Purpose Built Development Pipeline Advancing to Support Women at Every Stage of Life Commercial Inflection Point First product revenue expected in 2026 from Flora Syne LF
Slide 27: Daring to Put Her Health First
Daring to Put Her Health First™ DAREBIOSCIENCE.COM | NASDAQ: DARE ©2026 DARE BIOSCIENCE, ALL RIGHTS RESERVED
Slide 28: Appendix
Slide 29: FDA Approved Product: XACIATO
AREBIOSCIENCE FDA APPROVED PRODUCT: XACIATO™ (Clindamycin Phosphate) Vaginal Gel 2% PSOUHGH INES: XACIATO [zah-she-AH-toe] (clindamycin phosphate) vaginal gel 2% is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis (BV) in females 12 years of age and older* + Available n
Slide 30: XACIATO Selected Safety Information
AREBIOSCIENCE XACIATO™ (Clindamycin Phosphate) Vaginal Gel 2% SELECTED SAFETY INFORMATION XACIATO is contraindicated in individuals with a history of hypersensitivity to clindamycin or lincomycin. Clostridioides difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacter
Slide 31: Oral Sildenafil provided a compelling proof of concept for FSAD
AREBIOSCIENCE Oral Sildenafil provided a compelling proof of concept for FSAD STATISTICALLY SIGNIFICANT INCREASES STATISTICALLY SIGNIFICANT IMPROVEMENT IN VAGINAL PULSE AMPLITUBE (VPA)* IN GENITAL STIMULATION (FIEI)? 7 : + Question #2 — “After taking study medication, the Pfizer VPA Clinical Lab Stu
Slide 32: Path Forward for Sildenafil Cream for Treatment of FSAD
AREBIOSCIENCE Path Forward for Sildenafil Cream for Treatment of FSAD EXPLORATORY PHASE 2B CLINICAL STUDY' + The Phase 2b Clinical Study (ID# NCT04948151) was designed to evaluate Sildenafil Cream vs. placebo over 12 weeks. * To Daré's knowledge, this was the first study specifically evaluating a po
Slide 33: Sildenafil Cream Phase 2b in FSAD
AREBIOSCIENCE rv Sildenafil Cream Phase 2b in FSAD EXPLORATORY POST-HOC ANALYSES* Post-Hoc Analysis Results from Proposed Phase 3 population: FSAD with or without concomitant decreased desire Sildenafil Cre: Placebo Cream + Post-hoc analyses were conducted on enrollment female sexual Endpoint 3.6% (
Slide 34: Sildenafil Cream Phase 2b in FSAD: Safety Results
AREBIOSCIENCE rv Sildenafil Cream Phase 2b in FSAD SUMMARY OF SAFETY RESULTS Sildenafil Cream was well tolerated by exposed users and their sexual partners. + During the 12-week double-blind dosing period, there were 78 TEAEs reported by 29 of the 99 Sildenafil Cream-assigned participants and 65 TEA
Slide 35: Sildenafil Cream Pharmacokinetic and Pharmacodynamic Studies
AREBIOSCIENCE Sildenafil Cream, 3.6% Pharmacokinetic and Pharmacodynamic Studies PHASE 1 & PHASE 2A STUDY RESULTS THERMOGRAPHY STUDY RESULTS* Phase 1 Study of SST-6007 (Sildenafil Cream, 3.6%)* + Demonstrated time to effect (11-15 minutes) + Positive cognitive arousal responses were noted Significan
Slide 36: Notable Publications for Daré's Sildenafil Cream
AREBIOSCIENCE Notable Publications for Daré’s Sildenafil Cream, 3.6% UBLICATION Sexual Medicine, Volume 12, Issue 5, October 2024 Obstetrics & Gynecology. 144(2):p 144-152, August 2024. The Journal of Sexual Medicine. 2024 Sep 3;21(9):793-799. The Journal of Sexual Medicine. 2024 Jul 26; 21 (9): 787
Slide 37: Ovaprene: Pre-Pivotal Postcoital Test
AREBIOSCIENCE OVAPRENE® Investigational Hormone-Free Monthly Intravaginal Contraceptive OVAPRENEO PRE-PIVOTAL The Ovaprene® Pre-Pivotal Postcoital Test (PCT) study met its primary endpoint. + In 100% of women and cycles, Ovaprene prevented the requisite number of sperm from reaching the cervix. + As
Slide 38: Ovaprene: Regulatory Strategy
AREBIOSCIENCE OVAPRENE® Investigational Hormone-Free Monthly Intravaginal Contraceptive us. REGULATORY ‘STRATEGY! Based on our communications to date with the FDA, if successful, we believe only this single ongoing registration study will be sufficient to support a premarket approval application sub